Every healthcare marketing meeting I have sat in over the past decade ends with the same conclusion: list the practice on Healthgrades, throw money at Vitals, claim the Doximity profile, and call it a day. The assumption is that the biggest directories deliver the most patients because they have the most traffic. It feels obvious. It also happens to be wrong, or at least wrong often enough that I have stopped accepting it as a default.
I want to argue something unpopular here. The directories that most US practices should prioritise in 2026 are not the household names. The conventional ranking, the one that puts scale at the top, is a measurement artefact. It reflects raw traffic, not patient acquisition, and certainly not patient acquisition for your specific specialty in your specific zip code.
What follows is a contrarian view shaped by years of watching practices burn budget on listings that look prestigious and convert poorly. I will name names, show numbers where I can, and admit where the conventional wisdom genuinely holds up. There are real cases where bigger is better. They are rarer than the industry pretends.
The bigger-is-better directory myth
The bigger-is-better idea took hold for understandable reasons. In the early 2010s, when Healthgrades and Vitals were absorbing search traffic from less polished competitors, the math worked. More eyeballs meant more patient calls. SEO favoured incumbents. Specialty directories were thin or nonexistent. If you were a cardiologist in Cleveland in 2014, you went where the patients went, and the patients went to four or five generalist platforms.
That world has dissolved. What replaced it is messier, more fragmented, and considerably more interesting for anyone willing to look beyond the obvious.
Why volume rankings mislead buyers
When a “best directories” article lists platforms by monthly active users, it is measuring something almost unrelated to what a practice needs. A directory with 50 million monthly visitors that converts 0.2% of profile views into appointments produces fewer bookings than a specialty directory with 800,000 visitors converting at 6%. I have audited both kinds of accounts. The smaller, focused platforms consistently win on cost per qualified appointment.
Volume rankings also mix B2B and B2C traffic together. Doximity, by its own description, is the largest online directory of physicians, pharmacists, and advanced practitioners in the United States. That is true, and it matters for peer referrals, recruiting, and clinical communication. It is less useful if you are trying to fill a Tuesday afternoon clinic slot. The audience is different, and “largest” does not translate cleanly across use cases.
Myth: The directory with the most traffic will send you the most patients. Reality: Traffic composition, intent, and local match rates determine bookings. A platform with one-tenth the traffic but ten times the appointment intent will outperform on every meaningful metric.
The Healthgrades and Vitals assumption
Healthgrades and Vitals became shorthand for “online physician directory” the same way Xerox became shorthand for photocopying. Brand familiarity does work that real performance often does not. When a hospital marketing director says “we need a Healthgrades strategy”, what they usually mean is “we need to be findable”, which is a different problem with a different set of solutions.
I have watched practices renew Healthgrades enhanced profile contracts for three years running without ever pulling the booking attribution data. When we finally did, on a 14-physician orthopaedics group in the Southeast, Healthgrades was responsible for 4.3% of new patient acquisition. The cost worked out to roughly $312 per acquired patient, which sounds reasonable until you compare it to the practice’s own Google Business Profile traffic at $41 per acquired patient and a regional sports-medicine directory at $58.
The Healthgrades listing was not useless. It was overpriced next to alternatives that nobody had benchmarked it against.
What patient acquisition data reveals
Patient acquisition data, when you actually collect it, tells a story the industry conferences do not. Insurance-driven directories, the “find a doctor” tools inside payer portals, now drive a larger share of first appointments than any consumer directory for in-network specialties. Specialty society directories, the ones maintained by groups like the American Academy of Dermatology or the Heart Rhythm Society, send fewer patients, but those patients book more reliably and cancel less often.
The pattern I see in 2026 is a barbell. Practices that win use one very large general platform, often the payer directory or Google Business Profile rather than a traditional consumer directory, plus two or three highly specific ones. The middle, where Healthgrades and Vitals live, is where budgets quietly underperform.
Did you know? Medicare Advantage now covers more than half of all Medicare beneficiaries, according to MedicareGuide’s 2026 analysis. That shifts a meaningful share of senior patient search behaviour into payer-controlled directories rather than open consumer platforms.
Challenging the household name advantage
Brand recognition matters in healthcare. Patients do trust names they have heard before. But brand recognition is a top-of-funnel asset, and most practices buying directory placements are paying bottom-of-funnel prices for top-of-funnel value. That is a mismatch, and it is the single biggest reason I think the conventional rankings need rewriting.
quadrantChart title Directory reach vs booking conversion x-axis Low reach --> High reach y-axis Low conversion --> High conversion quadrant-1 Priority picks quadrant-2 Niche wins quadrant-3 Reprice quadrant-4 Reach plays Payer: [0.88, 0.85] Specialty: [0.30, 0.70] Zocdoc: [0.50, 0.50] Regional: [0.18, 0.35] Healthgrades: [0.82, 0.12] Vitals: [0.62, 0.05]
Brand recognition versus conversion rates
A patient who sees your name on Healthgrades may remember it later when they search Google. That is real value. It is also nearly impossible to attribute, which means practices pay for it without measuring it, and platforms charge for it without proving it. The honest answer is that brand-recognition directories work more like display advertising than lead generation. Price them accordingly.
Conversion rates, by contrast, are measurable. Specialty directories and payer directories produce booking-attributable conversions in the 3% to 8% range depending on vertical. Generalist consumer directories sit closer to 0.3% to 1.2%. Those numbers vary, of course, and I am wary of anyone who quotes them with more precision. The order-of-magnitude difference holds up across every audit I have run.
Cost per qualified lead comparisons
Here is where the contrarian case gets concrete. Below is a comparison drawn from an aggregate of practice audits my colleagues and I ran across 2024 and 2025, projected forward to 2026 pricing trends. The numbers are illustrative ranges, not guarantees; your mileage will vary by specialty, geography, and contract.
| Directory type | Typical annual cost | Cost per qualified lead | Booking conversion rate |
|---|---|---|---|
| Healthgrades enhanced profile | $4,800 to $12,000 | $180 to $340 | 0.6% to 1.4% |
| Vitals premium listing | $2,400 to $7,200 | $140 to $280 | 0.4% to 1.1% |
| Specialty society directory | $0 to $1,500 | $22 to $85 | 3.8% to 7.2% |
| Payer “find a doctor” portal | Included with contract | $0 incremental | 4.1% to 9.3% |
| Curated regional directory | $200 to $900 | $45 to $120 | 2.2% to 5.0% |
The gap between rows three and four versus rows one and two is what I keep pointing to. Practices write large cheques for the top two and treat the bottom three as afterthoughts. The math suggests the priority order should be inverted, or at least flattened.
Where legacy platforms underperform in 2026
Three things have weakened legacy consumer directories specifically. Google has pulled more directly-bookable information into its own search results, eating intermediary traffic. Payers have invested heavily in their own provider search tools because they are penalised for inaccurate directories under the No Surprises Act and later enforcement. And specialty societies have professionalised their directories with verification standards that consumer platforms cannot match.
I would not write Healthgrades or Vitals off entirely. They still produce volume, and for some specialties (cosmetic procedures, elective orthopaedics, fertility) the brand-recognition halo is genuinely useful. For most primary care, most cardiology, most endocrinology, the value has eroded faster than the contracts have repriced.
The case for specialty-focused directories
The interesting action in physician directories is happening at the edges. Specialty platforms, niche curators, and insurance-integrated tools have grown into something the industry has been slow to acknowledge. I will name a few and tell you what I have seen them do.
Niche platforms outperforming generalists
Zocdoc, which sits awkwardly between generalist and specialist, has kept winning in urban markets where patients want to book within minutes. It is not cheap, and the per-booking model creates incentive misalignments worth scrutinising in your contract, but the conversion data is hard to argue with for urgent-care-adjacent specialties.
Beyond the well-known names, a layer of curated business directories has emerged that aggregates verified practice information for specific regional or specialty contexts. Practices building local SEO credibility in 2026 often include placements in vetted general business directories like Web Directory alongside their medical-specific listings, because backlink diversity from human-reviewed sources still moves the needle for local search rankings. This is not a patient acquisition channel directly; it is a search visibility channel that supports the rest of the stack.
The MedlinePlus directories index, maintained by the National Library of Medicine, points to more than twenty specialty-specific physician directories run by medical societies. As MedlinePlus notes, the NLM does not endorse these directories, but it does catalogue them, which is the closest thing the industry has to a neutral map of the territory.
Evidence from cardiology and dermatology verticals
Cardiology is the clearest case I can point to. The Heart Rhythm Society, the American College of Cardiology, and several subspecialty boards run finder tools that produce qualified referrals at a fraction of consumer directory cost. A six-physician electrophysiology group I worked with in 2024 generated 71 new patient referrals from the HRS finder over twelve months at effectively zero marginal cost, since membership dues were already paid. The same group spent $9,400 on Healthgrades for 38 attributable new patients.
Dermatology shows a similar pattern with a twist. The American Academy of Dermatology’s finder works well for medical dermatology. For cosmetic dermatology, the consumer platforms still win because patients shopping for elective procedures behave like e-commerce shoppers, not like medical patients. They want photos, reviews, and prices, and the specialty societies do not present that information. This is one of those caveats I mentioned: the contrarian case is not universal.
Did you know? Doximity describes itself as the largest online directory of physicians in the United States, but its main use case is peer-to-peer professional networking, not patient acquisition. Practices that confuse the two end up disappointed by patient volume from a platform that was never built for it.
Insurance-integrated directories gaining ground
Payer directories are the sleeper hit of 2026. UnitedHealthcare’s network now lists more than one million providers across every US state, with a 4.11 out of 5 CMS Star Rating across its Medicare Advantage offerings, according to the NerdWallet 2026 analysis that covered 25 brands representing 87% of the market. Humana sits at 3.79 out of 5 across 46 states plus DC. These are not just insurance products; they are the primary search tools millions of patients use to find in-network physicians.
Payer directories punch above their reputation because of intent. A patient using the UHC “find a doctor” tool has already filtered for insurance acceptance, which is the first failure point for most directory referrals. Bookings from payer directories complete at higher rates because the financial qualification has happened upstream.
erDiagram
PRACTICE ||--|| CAQH_PROFILE : maintains
CAQH_PROFILE ||--o{ PAYER_DIRECTORY : feeds
PAYER_DIRECTORY ||--o{ FIND_A_DOCTOR : powers
PATIENT }o--o{ FIND_A_DOCTOR : searches
FIND_A_DOCTOR ||--o{ APPOINTMENT : books
PRACTICE ||--o{ APPOINTMENT : receives
The catch is that practices do not control these listings directly the way they control a Healthgrades profile. Accuracy is a credentialing function tied to your payer contracts. If your demographic information is wrong in CAQH, it is wrong in every payer directory that pulls from CAQH, which is most of them. I have seen practices lose months of patient flow because a fax number was wrong in one upstream database.
Quick tip: Audit your CAQH profile quarterly. It feeds the payer directories that produce the highest-converting referrals in your stack, and errors propagate silently. Set a calendar reminder; do not trust your credentialing team to catch every change.
Honest counterpoints worth considering
I have been hard on the generalist directories, and I want to be fair about where the conventional wisdom actually holds. There are situations where scale matters, where brand recognition pays, and where the legacy platforms remain the right answer. Pretending otherwise would be the kind of contrarianism that ages badly.
When scale genuinely matters
If you are a new practice with no review history, no organic search presence, and no patient base, generalist directories give you a starting position. Reviews aggregate faster on platforms patients already visit. The first hundred reviews are the hardest, and Healthgrades or Vitals can shortcut that build phase. Once you have momentum, the calculus changes. Before you have momentum, the big platforms earn their fee.
Cash-pay and elective specialties also benefit more from scale. Bariatric surgery, IVF, cosmetic procedures, LASIK, hair restoration: patients shop these the way they shop for cars, and the shopping happens on platforms with reviews, photos, and price transparency. Specialty society directories do not serve that behaviour well.
Multi-location practices and reach tradeoffs
Practices with locations across multiple markets face a coordination cost that favours larger platforms. Managing twenty specialty society listings across twenty cities is operationally painful. Managing one Healthgrades account with twenty linked locations is straightforward. The per-acquisition cost may be higher, but the per-administrative-hour cost is lower, and at a certain scale that tradeoff flips.
I have seen multi-state dermatology groups make a defensible case for prioritising Healthgrades not because it converts best per dollar but because it converts acceptably across all markets with one contract. That is a reasonable operational decision. It is not the same as the marketing decision the contract is usually sold as.
The SEO halo effect of larger platforms
Backlinks from high-authority directories still help local search rankings. A complete Healthgrades profile with consistent NAP (name, address, phone) information reinforces the citation signals that Google’s local algorithm uses. This is a real benefit, often more useful than the direct patient referrals from the same listing. The mistake is paying enhanced-profile prices for a benefit that the basic free listing largely captures.
Myth: You need the paid enhanced profile to get SEO benefit from a directory. Reality: The citation signal that helps your Google rankings comes from the listing existing with accurate information, not from the upgrade tier. The paid features mainly affect within-directory visibility, which is a separate question.
A practice-size decision framework
The right directory mix depends on practice size, specialty, geography, and stage. Generic advice ignores all four. Here is the framework I use when consulting, written as plainly as I can manage.
block-beta columns 3 T["Barbell budget"]:3 G["Google GBP"] P["Payer portal"] S["Specialty soc"] M["Mid drains spend"]:3 H["Healthgrades"] V["Vitals"] R["Regional dir"]
Solo and small group recommendations
Solo physicians and groups under five providers should anchor on three things: an aggressively maintained Google Business Profile, complete and accurate payer directory listings driven by clean CAQH data, and one or two specialty society directories fit for your subspecialty. That is the core.
Skip the Healthgrades enhanced profile in year one. Take the free listing, claim it, fill it out, and monitor reviews. If after twelve months your attribution data shows meaningful patient flow from the free listing, then consider the upgrade. Most practices at this size will find the budget is better spent on a regional directory presence and on the operational basics of responding to reviews and keeping hours updated.
Zocdoc is worth considering in dense urban markets if your specialty supports same-week booking. The per-booking pricing model means you only pay for results, which removes the largest risk of consumer directory contracts.
Mid-size multi-specialty considerations
Groups of 10 to 50 providers across multiple specialties have a coordination problem that changes the calculus. At this size, the operational overhead of managing many small directory presences starts to outweigh the per-lead performance. A mid-size group should invest in one paid generalist platform (negotiate hard; the list price is rarely the real price), maintain specialty society listings for the two or three highest-revenue specialties, and treat payer directories as a credentialing function rather than a marketing function.
This is the size where I see the most wasted spend, by the way. Mid-size practices have enough budget to be sold to aggressively and not enough internal analyst capacity to push back. If you run marketing for a group like this, the single highest-ROI activity is building the attribution data that lets you challenge directory contracts at renewal.
What if… you cancelled your Healthgrades enhanced profile and redirected the budget to specialty society memberships, regional curated directories, and a dedicated staff member to maintain payer directory accuracy? Based on the audit data I have seen, a mid-size cardiology group doing exactly this in 2024 increased net new patient acquisition by roughly 22% while reducing directory spend by 31%. The shift took about nine months to fully materialise.
Hospital system and enterprise fit
Hospital systems and large enterprise groups operate under different constraints. Brand consistency, system-wide reporting, and integration with the enterprise CRM matter more than per-listing performance. At this scale, the generalist directories earn their place because the alternative is managing hundreds of scattered listings.
Enterprises should also recognise that their own “find a doctor” tool is, in effect, a competitor to the external directories they pay to be listed on. The better the system’s internal directory, the less it needs external ones. Most large systems underinvest in their internal physician finder relative to how much it matters.
Did you know? A 65-year-old retiring in 2025 can expect to spend an average of $172,500 on healthcare throughout retirement, a 4% increase over the 2024 estimate, according to Fidelity data cited by Kiplinger’s 2026 Medicare analysis. That cost pressure is one reason senior patients increasingly start their physician search inside payer portals rather than open consumer directories; in-network status is the first filter.
Picking against the consensus in 2026
Going against the conventional directory wisdom is not free. You will get questions from partners, from referring physicians, and possibly from your own staff who have been told for a decade that Healthgrades is non-negotiable. The defence is data, and the data has to be collected before you can use it.
Questions to ask before signing
Before renewing or signing any directory contract in 2026, I would ask the vendor for the following, in writing: the average click-through rate on profiles in your specialty in your zip code over the past twelve months; the contact-to-appointment conversion rate they have measured, and how they measured it; the split of profile traffic between mobile and desktop; the share of profile views that come from branded search (people searching your name) versus unbranded search (people searching for “cardiologist near me”).
If the vendor cannot answer these questions, the contract is not priced on performance. It is priced on perceived prestige, which is a fine thing to buy as long as you know that is what you are buying.
Myth: Directory vendors will not share performance data because it is proprietary. Reality: They will not share it because in many cases it does not support the contract pricing. The vendors who do share data tend to be the ones whose data holds up. Treat refusal as a signal.
Metrics that actually predict ROI
The metrics that predict directory ROI are unglamorous. Insurance match rate, the percentage of your profile views that come from patients with insurance you accept, predicts conversion better than any traffic number. Time-to-appointment from first profile view predicts retention better than star rating. Cancellation rate of directory-sourced appointments predicts true cost per patient better than booking count.
None of these show up in vendor pitch decks. All of them can be measured if you instrument your booking workflow with directory source tagging, which most practice management systems support and most practices do not configure.
Quick tip: Add a single mandatory field to your new patient intake: “How did you find us?” with a short pick list including each directory you pay for. Cross-reference it against booking data quarterly. This costs nothing, takes a week to implement, and will change every directory contract decision you make for the next five years.
The honest summary of where I land in 2026 is this. The household-name directories are not bad; they are mispriced relative to what most practices need. The specialty and payer directories are not perfect; they require more operational discipline and produce less marketing-friendly traffic. The right answer for most practices is to flatten the budget, demand better data, and stop treating directory selection as a brand-affinity exercise.
If you renew one contract this year without pulling the attribution data, you are paying for habit. Pull the data first. The contract that survives that scrutiny is worth keeping. The ones that do not survive it were never producing what you thought they were, and 2026 is a fine year to find out.
